Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Protoc Microbiol. 2013;Chapter 14:Unit 14D.4. doi: 10.1002/9780471729259.mc14d04s28.

Retinal gene delivery by rAAV and DNA electroporation.

Author information

1
Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Abstract

Ocular gene therapy is a fast-growing area of research. The eye is an ideal organ for gene therapy since it is immune privileged and easily accessible, and direct viral delivery results primarily in local infection. Because the eye is not a vital organ, mutations in eye-specific genes tend to be more common. To date, over 40 eye-specific genes have been identified harboring mutations that lead to blindness. Gene therapy with recombinant adeno-associated virus (rAAV) holds the promise to treat patients with such mutations. However, proof-of-concept and safety evaluation for gene therapy remains to be established for most of these diseases. This unit describes the in vivo delivery of genes to the mouse eye by rAAV-mediated gene transfer and plasmid DNA electroporation. Advantages and limitations of these methods are discussed, and detailed protocols for gene delivery, required materials, and subsequent tissue processing methods are described.

PMID:
23408132
PMCID:
PMC3643812
DOI:
10.1002/9780471729259.mc14d04s28
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center